We supply Dirithromycin API

Dirithromycin is an active medicinal element that we supply. It's an antibiotic that belongs to the macrolide class. It works by inhibiting the growth and spread of bacteria in the body. It has been set up to be effective against a wide range of bacterial infections similar as respiratory tract infections, skin infections, and urinary tract infections. At our company, we specialize in the product and force of high- quality Dirithromycin API. We use state- of- the- art manufacturing processes and rigorous quality control measures to insure that our products meet the topmost morals of chastity and energy. Our platoon of experts is committed to furnishing our guests with the swish possible client service and support. Whether you are a pharmaceutical company or a exploration institution, we can supply you with the API that you need for your exploration and development purposes. still, look no further than our company, If you are looking for a dependable and secure supplier of this API. communicate us moment to learn further about our products and services.

What is Dirithromycin?

Dirithromycin, chemical name( 9S, 16R)-( imino(( 1R)- 2-( 2- methoxyethoxy) ethylidene) oxygen) erythromycin, is an organic emulsion with chemical formula C42H78N2O14. It's a macrolide antibiotic and a precursor medicine of erythromycin. It's a alternate- generation macrocyclic( fourteen membered ring) lactone antibiotic of the erythromycin class. It's formed by the condensation of 2- methoxyethoxyacetaldehyde and erythromycin at positions C9 and C11 to form an oxazine ring, and its structure is analogous to that of erythromycin. In vivo non enzymatic hydrolysis to erythromycin, it inhibits bacterial peptide conversion by binding to the 50S ribosomal subunit of sensitive pathogenic microorganisms, inhibits protein conflation, and is antibacterial. Compared with erythromycin and other new macrocyclic acetic acid antibiotics, this medicine has the following characteristics( 1) Antibacterial effect In addition to retaining its antibacterial effect on G- 10 bacteria, erythromycin still has strong antibacterial goods on colorful G- 1 bacteria, anaerobic bacteria, and other pathogens similar as mycoplasma, chlamydia, and spirochetes. The antibacterial goods of erythromycin on Staphylococcus aureus and Staphylococcus epidermidis are stronger or similar to those of erythromycin.( 2) Pharmacokinetics Compared with other macrocyclic acetic acid antibiotics, erythromycin has a longer partial- life, a tube elimination time tl/ 2 lower than 24 hours, and strong kerchief permeability, which can be administered once a day. thus, in the request, it'll also demonstrate competitiveness with characteristics that distinguish it from other antibiotics. Lilly's products were launched in Spain in September 1993, and were approved by the FDA for listing in the United States in 1996 and included in the US Pharmacopoeia USP23. They were launched domestically in 2005. At present, several domestic companies have approved the product and clinical use of erythromycin enteric carpeted tablets and capsules.

Basic Information

Product Name: Dirithromycin

CAS NO.: 62013-04-1

MF: C42H78N2O14

MW: 835.07

EINECS NO: 624-080-7

MDL No.: MFCD00865041

Purity: 99%+

MOQ: 1kg

Origin: China

Application: Antibiotic

Delivery Time: stock

Structural formula:

Melting point: 186-189 ° (dec) (Counter)

Boiling point: 871.8 ± 65.0 ° C (Predicted)

Density: 1.19 ± 0.1 g/cm3 (Predicted)

Solubility: Very slightly soluble in water, highly soluble in methanol and dichloromethane

Technical Specification:

Package: 1kg/bag; 10kg/drum; 25kg/drum

Storage conditions: Keep in dark place, Inert atmosphere,2-8°C

Safety Information

Dangerous goods labeling: Xn, Xi

Hazard category code: 42/43-36/37/38

Safety instructions: 36-26

WGK Germany: 3

Customs code: 29419000

Toxicity: LD50inmice(g/kg):>1s.c.;>1orally(Maier)

Synthetic route

Route 1: Erythromycin reacts with hydrazine hydrate to produce erythromycin hydrazone (2), which is then used to synthesize erythromycin amine (3). Finally, it reacts with 2-methoxyethoxyacetaldehyde (5) to synthesize erythromycin. As shown in the figure:

Route 2: Erythromycin reacts with hydroxylamine hydrochloride to obtain erythromycin oxime. The reduction of erythromycin oxime yields erythromycin amine, which is then condensed with 2- (2-methoxyethoxy) acetaldehyde ethylene glycol to form erythromycin (DRM). The specific reaction route is as follows:

Pharmacological action

Dirithromycin has an antibacterial spectrum similar to erythromycin. It has a strong inhibitory effect on Chlamydia and Mycoplasma, and its activity against most Gram positive bacteria is 2-4 times lower than that of erythromycin. The activity of erythromycin is four times stronger than that of erythromycin against pertussis bacilli. The in vitro anti Staphylococcal activity of erythromycin is similar to or less than that of erythromycin. It is less than or equal to 0.03-0.12 μ When g/ml, it can inhibit Streptococcus pyogenes and Streptococcus pneumoniae. Group B streptococci are also inhibited at the same concentration. Streptococcus pneumoniae and Listeria genus at 0.12 μ G/ml and 0.5 μ Inhibition was observed at g/ml. Group A Streptococcus, Listeria, and Enterococcus also exhibit resistance to erythromycin. The MIC90 of Staphylococcus aureus sensitive and resistant to erythromycin is 0.5 μ G/ml and 8 μ/ Ml. Erythromycin does not inhibit aerobic gram-positive bacteria. Generally speaking, the activity of erythromycin is 2-4 times higher than that of erythromycin. The activity of erythromycin against Staphylococcus and Streptococcus does not decrease with the addition of human serum. The activity of this class of macrolide drugs is 1-4 times higher at pH 8.0 than at pH 6.0. it has antibacterial activity against Staphylococcus aureus and a slow bactericidal effect on Haemophilus influenzae. Erythromycin is resistant to Enterococcus aureus and most methicillin-resistant Staphylococcus aureus, and has a close cross resistance relationship with other macrolide drugs.

What is the application of Dirithromycin

Erythromycin antibiotics

Semisynthetic antibiotics belonging to the macrolide class

Reference materials

[1] Li Lin et al. Preparation and in vitro release of erythromycin enteric coated pellets. Chinese Journal of Hospital Pharmacy, 2011, 31 (19): 1591-1595

[2] Yang Changhua et al. Determination of release rate of erythromycin enteric coated tablets. Journal of Hunan Normal University. 2014, 11 (4): 86-89

[3] Zhang Yudi et al. Long acting and safe macrolide antibiotic - erythromycin. Chinese Journal of Clinical Pharmacology, Chemalbook. 2011, 27 (6): 467-471

[4] Dierythromycin. Medical Encyclopedia

[5] Liang Yiheng. Synthesis of erythromycin. Chinese Journal of Pharmaceutical Industry. 2002, 33 (6): 269-270

[6] Liao Liang. Research on the synthesis of a new generation macrolide antibiotic, erythromycin. Dalian University of Technology Thesis. 1999

[7] Instruction manual for erythromycin enteric coated tablets

Contact information

as a supplier of Dirithromycin , Xi'an Yihui has rich production experience and technical knowledge, high-quality products, flexible production capacity, and quality customer service, which can provide better support and service to customers.

if you need it, pls feel free to contact us any time. we will reply you asap.

Our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937